Please login to the form below

Not currently logged in
Email:
Password:

Parkinson's

This page shows the latest Parkinson's news and features for those working in and with pharma, biotech and healthcare.

Lilly partners with AC Immune on tau drug for Alzheimer’s

Lilly partners with AC Immune on tau drug for Alzheimer’s

CHF 80m ($81m) upfront to license a tau-targeting candidate from Switzerland’s AC Immune. ... Aggregation of tau into 'tangles' is however a feature of a number of neurodegenerative diseases, including AD and Parkinson’s disease, and seems to

Latest news

More from news
Approximately 34 fully matching, plus 209 partially matching documents found.

Latest Intelligence

  • Key considerations for disease- modifying Parkinson’s disease trials Key considerations for disease- modifying Parkinsons disease trials

    ‘Lessons learnt from Alzheimer’s trials could help in Parkinson’s drug development’. ... Taking all these lessons learned into consideration should markedly lower the risk of a false negative result in clinical trials for disease-modifying

  • Tackling a formidable foe Tackling a formidable foe

    MAVENCLAD’S short-course oral therapy profile is a bonus to a condition freighted with psychological drag-weights. ... But the battle to beat MS continues at pace with the tantalising prospect that wins in the lab could also be translated to treatments

  • Six degrees of participation Six degrees of participation

    For example, a Parkinson’s patient recently told me that although he understood the importance of ‘participating’, he didn’t want to spend any more time than necessary thinking about ... That’s powerful evidence. And it’s right at our

  • A quest for innovative solutions A quest for innovative solutions

    It is this quest for technology that can help patients with epilepsy and Parkinson’s, the sweet spots in its global operation that saw total revenue grow to 4.2bn in ... We have huge support to translate that change for both others in the organisation

  • Pfizer and IBM's tech-enabled 'Parkinson’s house' Pfizer and IBM's tech-enabled 'Parkinsons house'

    But this elegant home, surrounded by manicured lawns, is wired to beat the scourge of Parkinson’s disease. ... This is a turning point for Parkinson’s.”. The success of BlueSky is important for both companies.

More from intelligence
Approximately 1 fully matching, plus 30 partially matching documents found.

Latest appointments

  • Prevail Therapeutics adds to its board of directors Prevail Therapeutics adds to its board of directors

    The Prevail team has already made great progress in developing potential treatments for Parkinson’s disease and other neurodegenerative diseases, and I look forward to partnering with the team to help

  • Voyager Therapeutics appoints Matthew Ottmer as chief operating officer Voyager Therapeutics appoints Matthew Ottmer as chief operating officer

    He said: “I am thrilled to join Voyager at this important time during the company’s evolution. ... Developing and implementing the initial commercial strategy and planning for VY-AADC for Parkinson’s disease is a top priority, especially as we

  • Newron Pharma appoints commercial affairs VP Newron Pharma appoints commercial affairs VP

    He brings sales and marketing experience from Johnson &Johnson, and served as franchise marketing director for psychiatry, Parkinson's disease and migraine products at Novartis. ... future. “At the same time we welcome Dennis as a new member of

  • Voyager Therapeutics appoints chief financial officer Voyager Therapeutics appoints chief financial officer

    This strong foundation combined with the company's recent positive interim phase Ib data from its lead program VY-AADC01 for advanced Parkinson's disease and the opportunity to join a ... I am thrilled to join the Voyager team and meaningfully contribute

  • Pfizer appoints chief scientific officer Pfizer appoints chief scientific officer

    Having first joined Harvard in 1989, Dr Isacson's work in neurogenerative disorders, particularly for Parkinson's disease, has become internationally renowned with his laboratory now one of the leading academic ... Dr Mikael Dolsten, president of

More from appointments
Approximately 1 fully matching, plus 22 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 9 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

The importance of co-creation with patients
Overcoming the barriers...
Three billboards on the road to multichannel
Chris Ross examines the trends driving multichannel communication in 2019...
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics